Blog Posts du Friday 30 Sep 2022

(Créé le vendredi 30 sept. 2022 15h07, Modifié le vendredi 30 sept. 2022 15h08).Translate

Asymmetric Information in Microeconomics

(Créé le vendredi 30 sept. 2022 14h13, Modifié le vendredi 30 sept. 2022 14h16).Translate

Sri Lanka ‘in a hurry’ to resume China
free-trade deal talks
to get ‘back on the radar’ after recent unrest

  • Talks between Beijing and Colombo over a free-trade agreement that began in 2014 have resumed, according to Sri Lankan ambassador to China, Palitha Kohona
  • Sri Lanka has been racked by civil unrest and economic disruptions, but this month reached a deal with the International Monetary Fund for a US$2.9 billion bailout
Read Also: Sri Lanka, IMF have agreed on a way out of nation’s economic hell. But what will it mean for the people? China’s debt leniency claim for developing nation ‘restructurings’ undercut by transparency issues

Cited Blog Post: How China-backed projects made Sri Lanka’s economic meltdown worse

https://www.scmp.com/economy/global-economy/article/3194408/sri-lanka-hurry-resume-china-free-trade-deal-talks-get-back

Sri Lanka, racked by civil unrest and economic disruptions for much of the year, has resumed free-trade agreement talks with China over the past two months amid new social stability within the island nation, the South Asian country’s ambassador in Beijing said on Friday.

“It’s been going on not at a high level, but at an official level,” Palitha Kohona told the Post.

“We are in a hurry because we would like to see more goods get access to the Chinese market.”

The two sides will consider an “asymmetric” trade deal that would address the small size of Sri Lanka’s economy compared to China’s and cover “low-hanging fruits” rather than every potential item eligible for import tariff cuts, Kohona added.

Talks that began in 2014 had reached a fifth round in 2017, when the two sides exchanged views on trade, investment and economic cooperation, according to the Chinese Ministry of Commerce.

The Chinese ministry lists its Sri Lanka free-trade agreement – China’s potential third in South Asia after Pakistan and the Maldives – as “under negotiation”.

China knows that Sri Lanka has gone “back to normal” following social unrest earlier in the year, Kohona said, and despite remaining financial issues, “Sri Lanka is much more stable than two or three months ago”.

(Créé le vendredi 30 sept. 2022 13h54, Modifié le vendredi 30 sept. 2022 14h10).Translate

O que é voto útil?

(Créé le vendredi 30 sept. 2022 12h24, Modifié le vendredi 30 sept. 2022 12h28).Translate

O que faz um Governador?

(Créé le vendredi 30 sept. 2022 12h01, Modifié le vendredi 30 sept. 2022 12h04).Translate

Repost du /blog/2022-05/08/fanatismo-por-lula-ou-bolsonaro-atrapalha-discussao-de-projeto-para-o-brasil-diz-heloisa-helena

(Créé le vendredi 30 sept. 2022 11h48, Modifié le vendredi 30 sept. 2022 11h48).Translate

See the Chords

(Créé le vendredi 30 sept. 2022 11h21, Modifié le vendredi 30 sept. 2022 11h22).Translate

(Créé le vendredi 30 sept. 2022 11h17, Modifié le vendredi 30 sept. 2022 11h17).Translate

(Créé le vendredi 30 sept. 2022 10h55, Modifié le vendredi 30 sept. 2022 10h55).Translate

See the Chords

(Créé le vendredi 30 sept. 2022 10h29, Modifié le vendredi 30 sept. 2022 10h32).Translate

Voir les Accords

(Créé le vendredi 30 sept. 2022 10h09, Modifié le vendredi 30 sept. 2022 10h10).Translate

(Créé le vendredi 30 sept. 2022 09h21, Modifié le vendredi 30 sept. 2022 09h22).Translate

(Créé le vendredi 30 sept. 2022 09h17, Modifié le vendredi 30 sept. 2022 09h18).Translate

(Créé le vendredi 30 sept. 2022 09h03, Modifié le vendredi 30 sept. 2022 09h03).Translate

(Créé le vendredi 30 sept. 2022 08h50, Modifié le vendredi 30 sept. 2022 08h51).Translate

(Créé le vendredi 30 sept. 2022 08h43, Modifié le vendredi 30 sept. 2022 08h44).Translate

China’s first mRNA Covid-19 vaccine approved
for use in Indonesia

  • Walvax’s AWcorna gets the go-ahead for emergency use by Indonesian authorities, and is ‘intensively’ advancing with Chinese regulator
  • Company chairman Li Yunchun says China has achieved full localisation and independent supply chain for the vaccine on the mainland
  • Walvax 的 AWcorna 获得印度尼西亚当局的紧急使用许可,并正在与中国监管机构“密集”推进
  • 公司董事长李云春表示,中国已实现疫苗在大陆的完全本地化和独立供应链

Cited Blog Post: About Policies of the Chinese Government with COVID-19 Vaccines - 关于中国政府关于 COVID-19 疫苗的政策

https://www.scmp.com/news/china/science/article/3194368/chinas-first-mrna-covid-19-vaccine-approved-use-indonesia

Indonesia has become the first country to approve a Chinese home-grown mRNA Covid-19 vaccine for emergency use.

The Indonesian Food and Drugs Agency on Thursday approved AWcorna for primary and booster use by people aged 18 years old and above, according to a report in China’s Communist Party mouthpiece People’s Daily.

The approval for the vaccine – co-developed by Yuxi Walvax with Suzhou Abogen Biosciences and the Academy of Military Science – is the first authorisation for a Chinese vaccine which uses the hi-tech platform adopted by Pfizer-BioNTech and Moderna.

China has yet to approve any mRNA vaccine although clinical trials have been approved for several. BioNTech, which partnered with Shanghai Fosun Pharmaceutical, has had its jab stuck in administrative review for a year.

Three years into the pandemic, more than 90 per cent of China’s 1.4 billion population have received two doses of Covid-19 shots and fewer than 60 per cent have had a booster, mostly with traditional inactivated vaccines.

According to the People’s Daily report, Walwax is intensively advancing emergency authorisation with the Chinese drug regulator. The company said earlier this year that it was still processing clinical trials data.

Indonesia has become the first country to approve a Chinese home-grown mRNA Covid-19 vaccine for emergency use.

The Indonesian Food and Drugs Agency on Thursday approved AWcorna for primary and booster use by people aged 18 years old and above, according to a report in China’s Communist Party mouthpiece People’s Daily.

The approval for the vaccine – co-developed by Yuxi Walvax with Suzhou Abogen Biosciences and the Academy of Military Science – is the first authorisation for a Chinese vaccine which uses the hi-tech platform adopted by Pfizer-BioNTech and Moderna.

China has yet to approve any mRNA vaccine although clinical trials have been approved for several. BioNTech, which partnered with Shanghai Fosun Pharmaceutical, has had its jab stuck in administrative review for a year.

Three years into the pandemic, more than 90 per cent of China’s 1.4 billion population have received two doses of Covid-19 shots and fewer than 60 per cent have had a booster, mostly with traditional inactivated vaccines.

According to the People’s Daily report, Walwax is intensively advancing emergency authorisation with the Chinese drug regulator. The company said earlier this year that it was still processing clinical trials data.
Advertisement

The AWcorna vaccine was developed in early 2020 and started late stage clinical trials in Indonesia in October. It has also been tested in Mexico and Guangxi province, southern China.

“At present, China has fully mastered the key core technology of mRNA vaccines, and has achieved full localisation and independent control in the whole supply chain, including the main raw and auxiliary materials and equipment,” Walwax chairman Li Yunchun said in the report.

No serious adverse events were recorded in phase one clinical trial data for the AWcorna vaccine, published in February by The Lancet Microbe.

印度尼西亚已成为第一个批准中国本土 mRNA Covid-19 疫苗用于紧急使用的国家。

据中国共产党喉舌《人民日报》报道,印度尼西亚食品和药物管理局周四批准 AWcorna 供 18 岁及以上人群初级和加强使用。

该疫苗的获批是由玉溪华科与苏州阿原生物科学和军事科学院共同开发的,是中国疫苗的首次授权,该疫苗使用了辉瑞-BioNTech和Moderna采用的高科技平台。

尽管已经批准了多项临床试验,但中国尚未批准任何 mRNA 疫苗。与上海复星医药合作的BioNTech在行政复议中被搁置了​​一年。

大流行三年后,中国 14 亿人口中超过 90% 的人接种了两剂 Covid-19 疫苗,不到 60% 的人接种了加强剂,主要是使用传统的灭活疫苗。

据《人民日报》报道,Walwax 正在与中国药品监管机构积极推进紧急授权。该公司今年早些时候表示,它仍在处理临床试验数据。

印度尼西亚已成为第一个批准中国本土 mRNA Covid-19 疫苗用于紧急使用的国家。

据中国共产党喉舌《人民日报》报道,印度尼西亚食品和药物管理局周四批准 AWcorna 供 18 岁及以上人群初级和加强使用。

该疫苗的获批是由玉溪华科与苏州阿原生物科学和军事科学院共同开发的,是中国疫苗的首次授权,该疫苗使用了辉瑞-BioNTech和Moderna采用的高科技平台。

尽管已经批准了多项临床试验,但中国尚未批准任何 mRNA 疫苗。与上海复星医药合作的BioNTech在行政复议中被搁置了​​一年。

大流行三年后,中国 14 亿人口中超过 90% 的人接种了两剂 Covid-19 疫苗,不到 60% 的人接种了加强剂,主要是使用传统的灭活疫苗。

据《人民日报》报道,Walwax 正在与中国药品监管机构积极推进紧急授权。该公司今年早些时候表示,它仍在处理临床试验数据。
广告

AWcorna 疫苗于 2020 年初开发,并于 10 月在印度尼西亚开始后期临床试验。它还在墨西哥和中国南方的广西省进行了测试。

“目前,中国已经完全掌握了mRNA疫苗的关键核心技术,并在包括主要原辅材料和设备在内的整个供应链上实现了完全国产化和自主可控,”沃尔蜡董事长李云春在报告中表示。

The Lancet Microbe 于 2 月发布的 AWcorna 疫苗的第一阶段临床试验数据中没有记录到严重的不良事件。

(Créé le vendredi 30 sept. 2022 08h23, Modifié le vendredi 30 sept. 2022 08h30).Translate

(Créé le vendredi 30 sept. 2022 08h05, Modifié le vendredi 30 sept. 2022 08h05).Translate

See the Chords

(Créé le vendredi 30 sept. 2022 07h50, Modifié le vendredi 30 sept. 2022 07h52).Translate

(Créé le vendredi 30 sept. 2022 06h52, Modifié le vendredi 30 sept. 2022 07h01).Translate